8,600
Total Claims
$1.8M
Drug Cost
916
Beneficiaries
$2,006
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+32%
Cost per patient vs peers
$2,006 vs $1,524 avg
-4%
Brand preference vs peers
13.0% vs 13.7% avg
Brand vs Generic
87% generic
Brand: 1,122 claims · $1.6M
Generic: 7,478 claims · $208K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tafamidis Meglumine | 23 | $480K |
| Apixaban | 338 | $455K |
| Rivaroxaban | 241 | $279K |
| Evolocumab | 92 | $105K |
| Alirocumab | 53 | $49K |
| Dronedarone Hcl | 29 | $47K |
| Ticagrelor | 45 | $43K |
| Sacubitril/Valsartan | 43 | $37K |
| Pitavastatin Calcium | 54 | $29K |
| Evolocumab | 29 | $22K |
| Icosapent Ethyl | 28 | $19K |
| Ezetimibe | 409 | $17K |
| Azilsartan Medoxomil | 26 | $14K |
| Metoprolol Succinate | 693 | $13K |
| Icosapent Ethyl | 22 | $13K |
Prescribing Profile
65
Unique Drugs
$770K
Patient Profile
76
Avg Age
43%
Female
1.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data